<ul>
<li>3 只生物科技股票可能受益于专利悬崖</li>
</ul>
<p>Beam Therapeutics（纳斯达克代码：BEAM）首席执行官约翰·埃文斯表示，公司正在推进其基础编辑平台在血液学和肝病项目中的应用，针对镰状细胞病候选药物的生物制剂许可申请可能在今年年底前提交。</p>
<p>获取 <strong>Beam Therapeutics</strong> 的提醒：</p>
<p>在 RBC 资本市场全球医疗会议上，与高级生物技术研究分析师卢卡·伊西的讨论中，埃文斯将 Beam 描述为一家 “下一代基因编辑公司”，专注于基础编辑，这是一种 CRISPR 形式，旨在对基因进行永久性的单字母更改，而不产生双链断裂。</p>
<ul>
<li>MarketBeat 周回顾 – 3/4 – 3/8</li>
</ul>
<p>埃文斯表示，这一区别可能使 Beam 能够进行 “更多的治疗性编辑” 和 “更精确的编辑”，包括将突变纠正回正常状态，而不仅仅是敲除基因。</p>
<h2>Alpha-1 项目显示剂量选择进展</h2>
<p>讨论的一个主要焦点是 BEAM-302，Beam 针对α-1 抗胰蛋白酶缺乏症的项目。埃文斯表示，该项目旨在将α-1 基因中的单字母拼写错误纠正回正常，这是第一次有人能够做到这一点。</p>
<ul>
<li>Beam Therapeutics 因基因治疗许可支付而大幅上涨</li>
</ul>
<p>埃文斯表示，早期数据表明，60 毫克剂量的α-1 水平超过 11 微摩尔，他将这一阈值描述为重要，因为没有疾病的携带者通常生活在这一水平之上，而患有进行性肺部和肝脏损伤的患者通常低于这一水平。</p>
<p>根据埃文斯的说法，围绕 60 毫克的额外剂量探索，包括 75 毫克剂量和两次 60 毫克的方案，并未产生有意义的额外药效益。他表示，结果确认 60 毫克是 Beam 希望使用的剂量。</p>
<p>埃文斯表示，较大的数据集显示，60 毫克剂量产生的平均α-1 水平为 16 微摩尔，正常的 M 蛋白水平超过 90%，Z 蛋白减少了 84%。</p>
<p>“我们显然并且显著地改变了疾病生理，至少达到了携带者的生理状态，” 埃文斯说，并补充道这支持了 Beam 的观点，即接受治疗的患者在未来不应经历进行性疾病。</p>
<h2>安全性和重新给药讨论</h2>
<p>伊西询问第二次 60 毫克剂量的耐受性，埃文斯表示其耐受性不如第一次。他表示，很难知道原因，指出前临床数据表明八周的时间应该足够让第一次脂质纳米颗粒剂量清除。然而，他表示α-1 肝脏可能在生理和巨噬细胞生物学上有所不同，可能保留了一些敏感性。</p>
<p>埃文斯将观察到的事件描述为可控的。他表示，Beam 观察到更高的输注相关反应，例如二级事件用莫特林治疗，以及一名患者出现无症状的三级 AST/ALT 升高，未需住院，未涉及胆红素变化，并迅速恢复。</p>
<p>埃文斯表示，他不认为这些发现表明脂质纳米颗粒重新给药是不可能的。他指出，Beam 仍计划对之前接受过亚治疗性 15 毫克和 30 毫克剂量的患者进行选定的 60 毫克剂量的重新给药。</p>
<p>关于肝酶升高，埃文斯表示，Beam 观察到的模式与 “经典的 LNP 信号” 一致，即肝酶迅速上升然后迅速下降。他表示，关键的安全考虑是几天内的快速改善和没有胆红素变化，而这正是 Beam 观察到的。</p>
<h2>旁观者编辑和蛋白功能</h2>
<p>埃文斯还回应了投资者关于旁观者编辑的问题。他表示，BEAM-302 可以产生纠正的 M 蛋白和 M 变体的混合物，这是 Beam 已知并随时间进行了表征的结果。</p>
<p>埃文斯表示，Beam 已经证明该变体正常分泌，功能正常，结构与正常 M 蛋白相当。他还表示，该变体位置在人群中常见，Beam 创造的特定变体在人群中存在，并且与疾病无关。</p>
<p>他指出，功能数据表明使用接受治疗患者的血清直接抑制人类中性粒细胞弹性蛋白酶，这表明该疗法产生的蛋白混合物是功能性的。</p>
<h2>监管路径和肝脏终点</h2>
<p>埃文斯表示，Beam 与 FDA 在 BEAM-302 的加速批准路径上达成了一致，将其描述为 “经典的加速批准” 策略，而不是依赖于新的监管机制。他表示，公司正在与稳定的 FDA 审查团队合作，FDA 的主要要求是进行 12 个月的跟踪，因为α-1 水平可能随时间变化。</p>
<p>埃文斯表示，Beam 计划招募 50 名患者，并在提交数据之前对他们进行一年的跟踪。他表示，生物标志物包包括总α-1 水平、M 蛋白水平、M 蛋白百分比、Z 蛋白减少、蛋白功能性和诱导性。</p>
<p>关于肝脏益处，埃文斯表示，Beam 相信 BEAM-302 可以通过提高功能性α-1 和降低 Z 蛋白来帮助α-1 抗胰蛋白酶缺乏症的肺部和肝脏表现。他表示，Beam 正在对 B 部分患者在治疗前和六个月、十二个月时进行活检，以评估聚集体是否消退以及纤维化是否随时间变化。</p>
<p>埃文斯表示，B 部分患者的肝病更为严重，迄今为止对药物的耐受性与 A 部分患者相似，支持全体患者的 C 组。</p>
<h2>镰状细胞项目和定价展望</h2>
<p>埃文斯表示，Beam 的体外镰状细胞病项目 risto-cel 可能在今年年底前提交 BLA 申请。他表示，Beam 相信其制造过程强大，静脉到静脉的时间仅略超过四个月，这可能使患者能够快速且可预测地接受治疗。</p>
<p>埃文斯表示，risto-cel 针对的是可能适合接受移植选项的重度镰状细胞患者，同时 Beam 也在继续研究可能在未来覆盖更广泛镰状细胞人群的体内治疗方法。</p>
<p>关于定价，埃文斯表示，Beam 将一次性 alpha-1 治疗的价格定得高于一年增补治疗的价格，但他指出，支付方非常成熟，会评估长期的药物经济学价值。他以镰状细胞病为例，指出高昂的终身治疗费用支持了基因医学的定价，同时强调现在讨论 alpha-1 的具体定价还为时尚早。</p>
<p>埃文斯表示，Beam 认为 alpha-1 抗胰蛋白酶缺乏症具有强大的价值故事，因为一次性治疗可能同时解决肺部和肝脏疾病。</p>
<h2>关于 Beam Therapeutics NASDAQ: BEAM</h2>
<p>Beam Therapeutics, Inc NASDAQ: BEAM 是一家致力于通过其开创性的碱基编辑平台开发精准基因医学的生物技术公司。公司总部位于马萨诸塞州剑桥市，并在费城设有额外的研究设施，专注于工程化分子编辑器，能够在 DNA 中进行精确的单核苷酸变化。通过利用其专有的碱基编辑技术，Beam 旨在在源头上纠正或破坏导致疾病的基因变异，为在重大未满足医疗需求领域提供新疗法的潜力。</p>
<p>Beam 成立于 2017 年，源自哈佛大学以及布罗德和怀特海德研究所，由领先的学术研究者大卫·R 共同创办。</p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元于 Beam Therapeutics 吗？</h2>
<p>在你考虑投资 Beam Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛市场注意到之前立即购买……而 Beam Therapeutics 并不在名单上。</p>
<p>虽然 Beam Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

BEAM

<p>Beam Therapeutics 正在推进其用于血液学和肝病的基础编辑平台，预计将在年底前提交其镰状细胞病候选药物的生物制剂许可申请。首席执行官 John Evans 强调了在 α-1 抗胰蛋白酶缺乏症项目中的进展，确认 60 毫克的剂量是有效的。该公司与 FDA 就 BEAM-302 的加速审批路径达成一致，计划招募 50 名患者进行进一步研究</p>

<ul>
<li>3 Biotech Stocks That Could Benefit from the Patent Cliff</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只生物科技股票可能受益于专利悬崖</li>
</ul>
</div><p>Beam Therapeutics NASDAQ: BEAM Chief Executive Officer John Evans said the company is advancing its base-editing platform across hematology and liver disease programs, with a potential biologics license application for its sickle cell disease candidate possible as early as the end of this year.</p>
<div class="lb-trans"><p>Beam Therapeutics（纳斯达克代码：BEAM）首席执行官约翰·埃文斯表示，公司正在推进其基础编辑平台在血液学和肝病项目中的应用，针对镰状细胞病候选药物的生物制剂许可申请可能在今年年底前提交。</p>
</div><p>Get <strong>Beam Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Beam Therapeutics</strong> 的提醒：</p>
</div><p>Speaking at RBC Capital Markets’ Global Healthcare Conference in a discussion with Senior Biotechnology Research Analyst Luca Issi, Evans described Beam as a “next-generation gene-editing company” focused on base editing, a form of CRISPR designed to make permanent single-letter changes in genes without creating a double-strand break.</p>
<div class="lb-trans"><p>在 RBC 资本市场全球医疗会议上，与高级生物技术研究分析师卢卡·伊西的讨论中，埃文斯将 Beam 描述为一家 “下一代基因编辑公司”，专注于基础编辑，这是一种 CRISPR 形式，旨在对基因进行永久性的单字母更改，而不产生双链断裂。</p>
</div><ul>
<li>MarketBeat Week in Review – 3/4 – 3/8</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周回顾 – 3/4 – 3/8</li>
</ul>
</div><p>Evans said that distinction could allow Beam to make “more therapeutic edits” and “more precise edits,” including correcting mutations back to normal rather than only knocking genes out.</p>
<div class="lb-trans"><p>埃文斯表示，这一区别可能使 Beam 能够进行 “更多的治疗性编辑” 和 “更精确的编辑”，包括将突变纠正回正常状态，而不仅仅是敲除基因。</p>
</div><h2>Alpha-1 Program Shows Dose Selection Progress</h2>
<div class="lb-trans"><h2>Alpha-1 项目显示剂量选择进展</h2>
</div><p>A major focus of the discussion was BEAM-302, Beam’s program for alpha-1 antitrypsin deficiency. Evans said the program is designed to correct the single-letter misspelling in the alpha-1 gene back to normal, which he said is the first time anyone has been able to do so.</p>
<div class="lb-trans"><p>讨论的一个主要焦点是 BEAM-302，Beam 针对α-1 抗胰蛋白酶缺乏症的项目。埃文斯表示，该项目旨在将α-1 基因中的单字母拼写错误纠正回正常，这是第一次有人能够做到这一点。</p>
</div><ul>
<li>Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments</li>
</ul>
<div class="lb-trans"><ul>
<li>Beam Therapeutics 因基因治疗许可支付而大幅上涨</li>
</ul>
</div><p>Evans said earlier data showed that a 60-milligram dose achieved alpha-1 levels above 11 micromolar, a threshold he described as important because carriers who do not have the disease generally live above that line, while patients with progressive lung and liver damage are usually below it.</p>
<div class="lb-trans"><p>埃文斯表示，早期数据表明，60 毫克剂量的α-1 水平超过 11 微摩尔，他将这一阈值描述为重要，因为没有疾病的携带者通常生活在这一水平之上，而患有进行性肺部和肝脏损伤的患者通常低于这一水平。</p>
</div><p>According to Evans, additional dose exploration around 60 milligrams, including a 75-milligram dose and a two-dose 60-milligram regimen, did not produce meaningful additional pharmacodynamic benefit. He said the results confirmed that 60 milligrams is the dose Beam wants to use.</p>
<div class="lb-trans"><p>根据埃文斯的说法，围绕 60 毫克的额外剂量探索，包括 75 毫克剂量和两次 60 毫克的方案，并未产生有意义的额外药效益。他表示，结果确认 60 毫克是 Beam 希望使用的剂量。</p>
</div><p>Evans said the larger data set showed the 60-milligram dose produced an average alpha-1 level of 16 micromolar, with normal M protein levels above 90% and Z protein reduced by 84%.</p>
<div class="lb-trans"><p>埃文斯表示，较大的数据集显示，60 毫克剂量产生的平均α-1 水平为 16 微摩尔，正常的 M 蛋白水平超过 90%，Z 蛋白减少了 84%。</p>
</div><p>“We had clearly and dramatically changed the disease physiology to at least a carrier physiology,” Evans said, adding that this supports Beam’s view that treated patients should not experience progressive disease going forward.</p>
<div class="lb-trans"><p>“我们显然并且显著地改变了疾病生理，至少达到了携带者的生理状态，” 埃文斯说，并补充道这支持了 Beam 的观点，即接受治疗的患者在未来不应经历进行性疾病。</p>
</div><h2>Safety and Redosing Discussed</h2>
<div class="lb-trans"><h2>安全性和重新给药讨论</h2>
</div><p>Issi asked about tolerability of a second 60-milligram dose, which Evans said was not as well tolerated as the first. Evans said it was difficult to know why, noting that preclinical data suggested eight weeks should have been enough time for the first lipid nanoparticle dose to clear. However, he said alpha-1 livers may differ in physiology and macrophage biology, potentially retaining some sensitivity.</p>
<div class="lb-trans"><p>伊西询问第二次 60 毫克剂量的耐受性，埃文斯表示其耐受性不如第一次。他表示，很难知道原因，指出前临床数据表明八周的时间应该足够让第一次脂质纳米颗粒剂量清除。然而，他表示α-1 肝脏可能在生理和巨噬细胞生物学上有所不同，可能保留了一些敏感性。</p>
</div><p>Evans characterized the observed events as manageable. He said Beam saw higher infusion-related reactions, such as grade two events treated with Motrin, and one patient with a grade three AST/ALT elevation that was asymptomatic, did not require hospitalization, did not involve bilirubin changes and resolved quickly.</p>
<div class="lb-trans"><p>埃文斯将观察到的事件描述为可控的。他表示，Beam 观察到更高的输注相关反应，例如二级事件用莫特林治疗，以及一名患者出现无症状的三级 AST/ALT 升高，未需住院，未涉及胆红素变化，并迅速恢复。</p>
</div><p>Evans said he did not believe the findings indicate that lipid nanoparticle redosing is not possible. He noted that Beam still plans to redose patients who previously received subtherapeutic 15-milligram and 30-milligram doses with the selected 60-milligram dose.</p>
<div class="lb-trans"><p>埃文斯表示，他不认为这些发现表明脂质纳米颗粒重新给药是不可能的。他指出，Beam 仍计划对之前接受过亚治疗性 15 毫克和 30 毫克剂量的患者进行选定的 60 毫克剂量的重新给药。</p>
</div><p>On liver enzyme elevations, Evans said the pattern Beam observed was consistent with a “classic LNP signal,” in which liver enzymes rise quickly and then fall quickly. He said the key safety considerations are rapid improvement within days and no bilirubin change, which he said Beam observed.</p>
<div class="lb-trans"><p>关于肝酶升高，埃文斯表示，Beam 观察到的模式与 “经典的 LNP 信号” 一致，即肝酶迅速上升然后迅速下降。他表示，关键的安全考虑是几天内的快速改善和没有胆红素变化，而这正是 Beam 观察到的。</p>
</div><h2>Bystander Editing and Protein Function</h2>
<div class="lb-trans"><h2>旁观者编辑和蛋白功能</h2>
</div><p>Evans also addressed investor questions about bystander editing. He said BEAM-302 can create a mixture of corrected M protein and an M variant, a result Beam has known about and characterized over time.</p>
<div class="lb-trans"><p>埃文斯还回应了投资者关于旁观者编辑的问题。他表示，BEAM-302 可以产生纠正的 M 蛋白和 M 变体的混合物，这是 Beam 已知并随时间进行了表征的结果。</p>
</div><p>Evans said Beam has shown that the variant is secreted normally, is functional and has a structure comparable to normal M protein. He also said the variant position is commonly varied in the human population and that the specific variant Beam creates is found in people and is not associated with disease.</p>
<div class="lb-trans"><p>埃文斯表示，Beam 已经证明该变体正常分泌，功能正常，结构与正常 M 蛋白相当。他还表示，该变体位置在人群中常见，Beam 创造的特定变体在人群中存在，并且与疾病无关。</p>
</div><p>He pointed to functional data showing direct inhibition of human neutrophil elastase using serum from treated patients, which he said demonstrated that the protein mixture created by the therapy is functional.</p>
<div class="lb-trans"><p>他指出，功能数据表明使用接受治疗患者的血清直接抑制人类中性粒细胞弹性蛋白酶，这表明该疗法产生的蛋白混合物是功能性的。</p>
</div><h2>Regulatory Path and Liver Endpoints</h2>
<div class="lb-trans"><h2>监管路径和肝脏终点</h2>
</div><p>Evans said Beam has alignment with the FDA on an accelerated approval path for BEAM-302, describing it as a “classic accelerated approval” strategy rather than one reliant on newer regulatory mechanisms. He said the company is working with stable FDA review teams and that the agency’s main request was for 12 months of follow-up because alpha-1 levels can vary over time.</p>
<div class="lb-trans"><p>埃文斯表示，Beam 与 FDA 在 BEAM-302 的加速批准路径上达成了一致，将其描述为 “经典的加速批准” 策略，而不是依赖于新的监管机制。他表示，公司正在与稳定的 FDA 审查团队合作，FDA 的主要要求是进行 12 个月的跟踪，因为α-1 水平可能随时间变化。</p>
</div><p>Evans said Beam plans to enroll 50 patients and follow them for one year before submitting the data. He said the biomarker package includes total alpha-1 levels, M protein levels, percentage of M protein, reduction in Z protein, protein functionality and inducibility.</p>
<div class="lb-trans"><p>埃文斯表示，Beam 计划招募 50 名患者，并在提交数据之前对他们进行一年的跟踪。他表示，生物标志物包包括总α-1 水平、M 蛋白水平、M 蛋白百分比、Z 蛋白减少、蛋白功能性和诱导性。</p>
</div><p>On liver benefit, Evans said Beam believes BEAM-302 could help both lung and liver manifestations of alpha-1 antitrypsin deficiency by raising functional alpha-1 and lowering Z protein. He said Beam is conducting biopsies in Part B patients before treatment and at six and 12 months to assess whether aggregates resolve and whether fibrosis changes over time.</p>
<div class="lb-trans"><p>关于肝脏益处，埃文斯表示，Beam 相信 BEAM-302 可以通过提高功能性α-1 和降低 Z 蛋白来帮助α-1 抗胰蛋白酶缺乏症的肺部和肝脏表现。他表示，Beam 正在对 B 部分患者在治疗前和六个月、十二个月时进行活检，以评估聚集体是否消退以及纤维化是否随时间变化。</p>
</div><p>Evans said the Part B patients, who have more advanced liver disease, have so far tolerated the drug similarly to Part A patients, supporting an all-comer Cohort C.</p>
<div class="lb-trans"><p>埃文斯表示，B 部分患者的肝病更为严重，迄今为止对药物的耐受性与 A 部分患者相似，支持全体患者的 C 组。</p>
</div><h2>Sickle Cell Program and Pricing Outlook</h2>
<div class="lb-trans"><h2>镰状细胞项目和定价展望</h2>
</div><p>Evans said Beam’s ex vivo sickle cell disease program, risto-cel, could have a BLA filing as early as the end of this year. He said Beam believes it has a strong manufacturing process, with a vein-to-vein time of just over four months, which he said could allow patients to be treated quickly and predictably.</p>
<div class="lb-trans"><p>埃文斯表示，Beam 的体外镰状细胞病项目 risto-cel 可能在今年年底前提交 BLA 申请。他表示，Beam 相信其制造过程强大，静脉到静脉的时间仅略超过四个月，这可能使患者能够快速且可预测地接受治疗。</p>
</div><p>Evans said risto-cel is aimed at severe sickle cell patients who may be candidates for a transplant-based option, while Beam also continues to work on in vivo approaches that could reach a broader sickle cell population over time.</p>
<div class="lb-trans"><p>埃文斯表示，risto-cel 针对的是可能适合接受移植选项的重度镰状细胞患者，同时 Beam 也在继续研究可能在未来覆盖更广泛镰状细胞人群的体内治疗方法。</p>
</div><p>On pricing, Evans said Beam would price a one-time alpha-1 therapy higher than one year of augmentation therapy, but said payers are sophisticated and evaluate long-term pharmacoeconomic value. He cited sickle cell disease as an example where high lifetime costs have supported genetic medicine pricing, while noting that it is too early to discuss specific pricing for alpha-1.</p>
<div class="lb-trans"><p>关于定价，埃文斯表示，Beam 将一次性 alpha-1 治疗的价格定得高于一年增补治疗的价格，但他指出，支付方非常成熟，会评估长期的药物经济学价值。他以镰状细胞病为例，指出高昂的终身治疗费用支持了基因医学的定价，同时强调现在讨论 alpha-1 的具体定价还为时尚早。</p>
</div><p>Evans said Beam believes alpha-1 antitrypsin deficiency has a strong value story because a one-time therapy could potentially address both lung and liver disease.</p>
<div class="lb-trans"><p>埃文斯表示，Beam 认为 alpha-1 抗胰蛋白酶缺乏症具有强大的价值故事，因为一次性治疗可能同时解决肺部和肝脏疾病。</p>
</div><h2>About Beam Therapeutics NASDAQ: BEAM</h2>
<div class="lb-trans"><h2>关于 Beam Therapeutics NASDAQ: BEAM</h2>
</div><p>Beam Therapeutics, Inc NASDAQ: BEAM is a biotechnology company dedicated to developing precision genetic medicines through its pioneering base editing platform. Headquartered in Cambridge, Massachusetts, with additional research facilities in Philadelphia, the company focuses on engineering molecular editors capable of making precise single-nucleotide changes in DNA. By harnessing its proprietary base editing technology, Beam aims to correct or disrupt disease-causing genetic variants at their source, offering the potential for novel therapies in areas with significant unmet medical need.</p>
<div class="lb-trans"><p>Beam Therapeutics, Inc NASDAQ: BEAM 是一家致力于通过其开创性的碱基编辑平台开发精准基因医学的生物技术公司。公司总部位于马萨诸塞州剑桥市，并在费城设有额外的研究设施，专注于工程化分子编辑器，能够在 DNA 中进行精确的单核苷酸变化。通过利用其专有的碱基编辑技术，Beam 旨在在源头上纠正或破坏导致疾病的基因变异，为在重大未满足医疗需求领域提供新疗法的潜力。</p>
</div><p>Founded in 2017 as a spin-out from Harvard University and the Broad and Whitehead Institutes, Beam was co-founded by leading academic researcher David R.</p>
<div class="lb-trans"><p>Beam 成立于 2017 年，源自哈佛大学以及布罗德和怀特海德研究所，由领先的学术研究者大卫·R 共同创办。</p>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Beam Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元于 Beam Therapeutics 吗？</h2>
</div><p>Before you consider Beam Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑投资 Beam Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Beam Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛市场注意到之前立即购买……而 Beam Therapeutics 并不在名单上。</p>
</div><p>While Beam Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Beam Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Beam Therapeutics 在 Alpha-1 基因编辑项目取得进展的同时，关注镰状细胞病的生物制剂许可申请